rs4149268 — ABCA1

Intronic ABCA1 variant — the C allele tags a liver enhancer that boosts ABCA1 expression, raising HDL-cholesterol; T-allele homozygotes show modestly lower HDL and elevated cognitive decline risk

See your personal result for ABCA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ABCA1 — The Cholesterol Efflux Gatekeeper

ABCA111 ATP-Binding Cassette Transporter A1 — a cell-membrane protein that pumps cholesterol and phospholipids out of cells onto lipid-poor apolipoprotein A-I, creating nascent HDL particles is the rate-limiting step in reverse cholesterol transport22 reverse cholesterol transport
the process by which cholesterol is removed from peripheral tissues and delivered to the liver for excretion. Without ABCA1, cells cannot shed excess cholesterol and HDL formation collapses. Loss-of-function mutations in both copies of ABCA1 cause Tangier disease33 Tangier disease
a rare autosomal recessive disorder characterized by near-absent HDL, orange-tinged tonsils, and accelerated atherosclerosis; heterozygous carriers have roughly half-normal HDL levels. rs4149268 operates at a far milder scale — it is a common intronic variant that fine-tunes how much ABCA1 the liver makes.

The Mechanism

rs4149268 sits in intron 2 of ABCA1 on chromosome 9 (GRCh38 position 104,884,939). The gene is transcribed from the minus strand, so the C allele reported in genome files (plus-strand) corresponds to a G in coding-strand notation as used in many papers — these are the same allele. Functional studies identified a nearby variant, rs2575875, in near-perfect linkage disequilibrium (r²=0.96) with rs4149268. Richardson et al.44 Richardson et al.
Richardson et al. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLOS One, 2019 showed that the A allele of rs2575875 (tagging the C allele of rs4149268) creates a STAT355 Signal Transducer and Activator of Transcription 3 — a transcription factor that activates gene expression in response to cytokines and growth factors binding site within an intronic enhancer that loops physically to the ABCA1 promoter. Chromatin immunoprecipitation showed 8-fold enrichment of this allele with anti-STAT3 antibody, and the enhancer drove allele-specific transcription in liver cell lines. Higher ABCA1 expression means more efficient cholesterol efflux and more nascent HDL particles.

The Evidence

The landmark GWAS meta-analysis by Willer et al.66 landmark GWAS meta-analysis by Willer et al.
Willer et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nature Genetics, 2008 in 8,816 individuals (with replication in 11,569) found that rs4149268-C carriers had approximately +0.82 mg/dL higher HDL-cholesterol compared to T/T homozygotes (p=10⁻¹⁰). The effect is small in absolute terms — HDL levels typically range from 40 to 80 mg/dL — but the association was genome-wide significant and biologically coherent with the ABCA1 pathway.

Replication in diverse populations has been mixed: the PAGE study77 PAGE study
Dumitrescu et al. Genetic determinants of lipid traits in diverse populations from the PAGE study. PLOS Genetics, 2011 could not replicate the association in European Americans despite 99% statistical power, suggesting the effect may be smaller than the original estimate implied or population-specific. The T allele reaches ~67% frequency in African populations (versus ~38% in Europeans), which affects absolute HDL distribution in those ancestries.

A study in a Chinese cohort (n=1,654) found that TT homozygotes were 1.76 times more likely to have mild cognitive impairment88 mild cognitive impairment
MCI — a clinically recognized transitional state between normal aging cognition and dementia, with impairment in memory or other domains that does not yet meet dementia criteria than CC homozygotes (OR 1.76, 95% CI 1.11–2.80). This likely reflects the known link between chronically low HDL and neurodegeneration, as ABCA1 drives cholesterol efflux in neurons and astrocytes, not just hepatocytes.

Practical Actions

The effect size of rs4149268 on HDL is modest — roughly 0.82 mg/dL per C allele. For TT homozygotes, the genotype itself is not a clinical diagnosis of low HDL; many TT individuals have perfectly normal HDL levels due to lifestyle and other genetic factors. The priority is knowing your measured HDL, then targeting the lifestyle drivers that have the largest HDL-raising effect in people with genetically modest ABCA1 activity: regular aerobic exercise (the strongest HDL lifter), reduction of trans fats, and niacin-equivalent dietary choices. If HDL is confirmed low, discussion with a clinician about whether pharmacological support is appropriate is warranted.

Interactions

ABCA1 does not act alone. APOE ε499 APOE ε4
rs429358 C allele — the APOE4 determinant that impairs LDL clearance and amyloid removal and ABCA1 T-allele homozygosity converge on the same pathway: both reduce brain cholesterol homeostasis and are independent risk factors for cognitive decline. Carrying ABCA1 TT alongside APOE4 may produce additive vulnerability to neurodegeneration, though direct compound studies at these two loci specifically are limited. The R219K variant in ABCA1 (rs2230806), studied extensively for HDL effects, acts through a different mechanism (missense, not enhancer regulation) and can interact with rs4149268 within the same gene.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC High Efflux Beneficial

Favorable ABCA1 activity — genetically higher HDL tendency

The C allele at rs4149268 is in near-perfect LD (r²=0.96) with the A allele of rs2575875, an intronic enhancer variant that creates a functional STAT3 binding site. STAT3 binding drives allele-specific transcription of ABCA1 in liver cells, increasing the transporter's expression and improving the rate of cellular cholesterol loading onto apolipoprotein A-I to form nascent HDL particles.

In the Willer et al. GWAS meta-analysis (n > 20,000), each C allele was associated with approximately +0.82 mg/dL higher HDL-C at genome-wide significance (p=10⁻¹⁰). In African populations, the T allele is much more common (~67%), making CC homozygosity more distinctly favorable in that context.

CT Intermediate Efflux Intermediate

One copy of the HDL-favoring C allele — average cholesterol efflux

Because rs4149268 shows additive dosage effects on HDL-C, CT heterozygotes fall between CC and TT genotypes. Each T allele substitution reduces the number of high-efficiency ABCA1 enhancer copies, modestly reducing hepatic cholesterol efflux capacity. For most CT carriers, this is a background factor rather than a clinically actionable finding — diet, aerobic exercise, and weight have far larger HDL effects than this single intronic variant.

TT Reduced Efflux Reduced

Two copies of the lower-HDL T allele — reduced ABCA1 enhancer activity

TT homozygotes are missing both copies of the rs2575875-linked STAT3 enhancer. Without this enhancer allele, ABCA1 transcription in liver cells is less efficient, reducing the rate at which cells export cholesterol onto apolipoprotein A-I to form HDL particles. Over decades, chronically lower HDL correlates with greater cardiovascular event risk and impaired reverse cholesterol transport.

The cognitive impairment finding (OR 1.76, 95% CI 1.11–2.80 in a Chinese cohort) is biologically plausible: ABCA1 is highly expressed in the brain, where it drives cholesterol efflux from neurons and astrocytes. Chronically reduced ABCA1 activity can impair neuronal membrane cholesterol homeostasis and, in combination with APOE genotype, increase amyloid burden.

The original GWAS effect size of ~0.82 mg/dL per allele is modest. If your measured HDL is normal, the genotype is a background risk factor rather than an indication for treatment. If HDL is confirmed low, targeted interventions can substantially raise it.